Jonathan E. Shoag

Jonathan E. Shoag

Auto-generated profile, based on publicly available information

Jonathan E. Shoag

Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2024 in Urology
Verified
Journal Article
Closed access
JMJack C. Millot
Jack C. Millot
CACamilo Arenas-Gallo
Camilo Arenas-Gallo
ESEsther Silver
Esther Silver
MGMollie Goldman
Mollie Goldman
SPShany Picciotto
Shany Picciotto
JSJonathan E. Shoag
Jonathan E. Shoag

1 February 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
TMTing Martin Ma
Ting Martin Ma
YSYilun Sun
Yilun Sun
SMShawn Christopher Malone
Shawn Christopher Malone
MRMack Roach
Mack Roach
DDDavid Dearnaley
David Dearnaley
OIon behalf of the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators
on behalf of the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators
PURPOSE: The sequencing of androgen-deprivation therapy (ADT) with radiotherapy (RT) may affect outcomes for prostate cancer in an RT-field size-dependent manner. Herein, we investigate the impact of ADT sequencing for men receiving ADT with prostate-only RT (PORT) or whole-pelvis RT (WPRT). MATERIALS AND METHODS: Individual patient data from 12 randomized trials that included patients receiving neoadjuvant/concurrent or concurrent/adjuvant short-term ADT (4-6 months) with RT for localized disease were obtained from the Meta-Analysis of Randomized trials in Cancer of the Prostate consortium. Inverse probability of treatment weighting (IPTW) was performed with propensity scores derived from age, initial prostate-specific antigen, Gleason score, T stage, RT dose, and mid-trial enrollment year. Metastasis-free survival (primary end point) and overall survival (OS) were assessed by IPTW-adjusted Cox regression models, analyzed independently for men receiving PORT versus WPRT. IPTW-adjusted Fine and Gray competing risk models were built to evaluate distant metastasis (DM) and prostate cancer–specific mortality. RESULTS: Overall, 7,409 patients were included (6,325 neoadjuvant/concurrent and 1,084 concurrent/adjuvant) with a median follow-up of 10.2 years (interquartile range, 7.2-14.9 years). A significant interaction between ADT sequencing and RT field size was observed for all end points ( P interaction < .02 for all) except OS. With PORT (n = 4,355), compared with neoadjuvant/concurrent ADT, concurrent/adjuvant ADT was associated with improved metastasis-free survival (10-year benefit 8.0%, hazard ratio [HR], 0.65; 95% CI, 0.54 to 0.79; P < .0001), DM (subdistribution HR, 0.52; 95% CI, 0.33 to 0.82; P = .0046), prostate cancer–specific mortality (subdistribution HR, 0.30; 95% CI, 0.16 to 0.54; P < .0001), and OS (HR, 0.69; 95% CI, 0.57 to 0.83; P = .0001). However, in patients receiving WPRT (n = 3,049), no significant difference in any end point was observed in regard to ADT sequencing except for worse DM (HR, 1.57; 95% CI, 1.20 to 2.05; P = .0009) with concurrent/adjuvant ADT. CONCLUSION: ADT sequencing exhibits a significant impact on clinical outcomes with a significant interaction with field size. Concurrent/adjuvant ADT should be the standard of care where short-term ADT is indicated in combination with PORT.

15 May 2022 in NEJM Evidence
Verified
Journal Article
Closed access
SBSpyridon P. Basourakos
Spyridon P. Basourakos
RGRoman Gulati
Roman Gulati
RVRandy A. Vince
Randy A. Vince
DSDaniel E. Spratt
Daniel E. Spratt
PLPatrick J. Lewicki
Patrick J. Lewicki
JSJonathan E. Shoag
Jonathan E. Shoag
BackgroundProstate-specific antigen screening has profoundly affected the epidemiology of prostate cancer in the United States. Persistent racial disparities in outcomes for Black men warra... Prostate Cancer Screening Harm-to-Benefit in Black MenThe authors estimated prostate cancer overdiagnoses and overtreatment for all races and for Black men 50 to 84 years of age until 2016, by calc...

27 August 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
DODaniel O’bRian
Daniel O’bRian
MPMegan Prunty
Megan Prunty
AHAlexander Hill
Alexander Hill
JSJonathan Shoag
Jonathan Shoag
C-Reactive Protein (CRP) is associated with diverse outcomes in patients with, or suspected to have, genitourinary malignancies. CRP levels have been shown to be associated with the probability of a prostate cancer diagnosis in patients with elevated PSA, the probability of biochemical recurrence following definitive treatment for localized prostate cancer, and decreased overall survival for patients with advanced disease. In patients with bladder and kidney cancers, CRP levels have been associated with disease progression, stage, and cancer-specific survival. Despite the abundance of correlative studies, the relationship between CRP levels and genitourinary cancer pathogenesis is not clearly understood. Here, we review the evidence for CRP as a biomarker in genitourinary (GU) cancers, with specific focus on potential clinical applications.

25 October 2021 in JCO Clinical Cancer Informatics
Verified
Journal Article
Closed access
SASajjad Abedian
Sajjad Abedian
ESEvan T. Sholle
Evan T. Sholle
PAPrakash M. Adekkanattu
Prakash M. Adekkanattu
MCMarika M. Cusick
Marika M. Cusick
SWStephanie E. Weiner
Stephanie E. Weiner
TCThomas R. Campion
Thomas R. Campion
PURPOSE: Typically stored as unstructured notes, surgical pathology reports contain data elements valuable to cancer research that require labor-intensive manual extraction. Although studies have described natural language processing (NLP) of surgical pathology reports to automate information extraction, efforts have focused on specific cancer subtypes rather than across multiple oncologic domains. To address this gap, we developed and evaluated an NLP method to extract tumor staging and diagnosis information across multiple cancer subtypes. METHODS: The NLP pipeline was implemented on an open-source framework called Leo. We used a total of 555,681 surgical pathology reports of 329,076 patients to develop the pipeline and evaluated our approach on subsets of reports from patients with breast, prostate, colorectal, and randomly selected cancer subtypes. RESULTS: Averaged across all four cancer subtypes, the NLP pipeline achieved an accuracy of 1.00 for International Classification of Diseases, Tenth Revision codes, 0.89 for T staging, 0.90 for N staging, and 0.97 for M staging. It achieved an F1 score of 1.00 for International Classification of Diseases, Tenth Revision codes, 0.88 for T staging, 0.90 for N staging, and 0.24 for M staging. CONCLUSION: The NLP pipeline was developed to extract tumor staging and diagnosis information across multiple cancer subtypes to support the research enterprise in our institution. Although it was not possible to demonstrate generalizability of our NLP pipeline to other institutions, other institutions may find value in adopting a similar NLP approach—and reusing code available at GitHub—to support the oncology research enterprise with elements extracted from surgical pathology reports.

9 August 2022 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
CACamilo Arenas-Gallo
Camilo Arenas-Gallo
JOJude Owiredu
Jude Owiredu
IWIlon Weinstein
Ilon Weinstein
PLPatrick Lewicki
Patrick Lewicki
SBSpyridon Basourakos
Spyridon Basourakos
JSJonathan E. Shoag
Jonathan E. Shoag